Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based ...
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of ...
Background Adverse childhood experiences (ACEs) are linked to poor health and social outcomes, with growing interest in their ...
Here are five tips for marketing leaders who want to use storytelling to drive understanding, engagement and trust.
Merck’s enlicitide decanoate significantly reduced LDL-C in adults with heterozygous familial hypercholesterolemia in phase 3 CORALreef HeFH trial: Rahway, New Jersey Tuesday, N ...
Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...
Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...
A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial ...
Initiating CPR within the first five minutes after cardiac arrest can nearly double the chances of survival for children, according to preliminary research analyzing data for more than 10,000 children ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback